文献速递前列腺癌

局部高危前列腺癌转录组分析改善预后并识别多西他赛联合放疗获益人群

Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial.
PubMed 文献 · Eur Urol Oncol · 2025-07-17

NRG/RTOG 0521 Ⅲ期试验随机分配高危局部前列腺癌患者接受雄激素抑制联合根治性放疗±多西他赛化疗。本研究在治疗前活检样本中验证 Decipher 基因组分类器(GC)的预后价值,并探索基底/腔细胞亚型对多西他赛反应的预测作用。结果显示 GC 评分独立与远处转移和无转移生存相关,腔增殖型肿瘤可能从化疗中获益。

要点

  • Decipher GC 评分独立与远处转移和无转移生存相关。
  • 未检测到 GC 与多西他赛的治疗交互作用。
  • 腔增殖型肿瘤接受化疗的 10 年 OS 限制平均生存时间差异为 13.7 个月(p=0.053)。

核心结论

  • Decipher GC 评分独立与远处转移和无转移生存相关。
  • 腔增殖型肿瘤可能从添加化疗中获益。

研究设计与样本

  • NRG/RTOG 0521 Ⅲ期随机试验的转化分析,获得 283 例患者样本,其中 183 例有 GC 评分。

主要发现

  • 中位随访 9.9 年,观察到 67 例转移事件,包括 34 例远处转移事件。
  • 多变量分析显示 GC 独立与远处转移相关(亚分布风险比 1.45)和无转移生存相关(风险比 1.20)。
  • 未检测到 GC 与多西他赛的治疗交互作用。
  • 化疗组 10 年 OS 限制平均生存时间差异在腔增殖型肿瘤为 13.7 个月(p=0.053),非腔增殖型为 2.5 个月(p=0.63)。

临床怎么用

  • Decipher GC 可用于高危局部前列腺癌的风险分层。
  • 腔增殖型亚型可能帮助筛选适合在多西他赛联合方案中获益的患者。

局限性

  • 样本量有限,仅 183 例获得 GC 评分。
  • 腔增殖型肿瘤化疗获益的 p 值为 0.053,未达到统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: NRG/RTOG 0521 randomized men with high-risk localized prostate cancer (PC) to androgen suppression (AS) and definitive radiotherapy (RT) ± docetaxel-based chemotherapy (CT). The overall survival (OS) benefit with CT initially reported was lost on longer follow-up. The Decipher genomic classifier (GC) measures multiple transcripts relevant to docetaxel action. Basal/luminal differentiation portends differential response to AS and CT for high-risk localized and metastatic hormone-sensitive PC. We validated the Decipher GC in pretreatment biopsy samples for risk stratification and examined basal-luminal subtyping to predict docetaxel response. METHODS: Decipher GC scores and basal-luminal cellular subtypes were generated for specimens from NRG/RTOG 0521. The primary objective was to validate the independent prognostic ability of GC for metastasis-free survival (MFS). Treatment effects in luminal proliferating (LP) and non-LP cell subtypes were examined in relation to MFS, OS, and distant metastasis (DM). KEY FINDINGS AND LIMITATIONS: Samples were obtained from 283 patients and yielded 183 GC scores. Over median follow-up of 9.9 yr, 67 metastasis events were observed, including 34 DM events. Multivariable analysis revealed that GC was independently associated with DM (subdistribution hazard ratio 1.45) and MFS (hazard ratio 1.20). No biomarker-by-treatment interaction with GC and docetaxel was detected. The 10-yr restricted mean survival time difference in OS with CT was 13.7 mo for LP (p = 0.053) and 2.5 mo for non-LP (p = 0.63) tumors. CONCLUSIONS AND CLINICAL IMPLICATIONS: The Decipher GC score was independently associated with DM and MFS, and LP tumors may benefit from addition of CT. Validation of these findings may allow more effective use of CT in men with localized PC. The original NRG/RTOG 0521 trial is registered on ClinicalTrials.gov as NCT00288080.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Phillips RM, Proudfoot JA, Davicioni E, et al. Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial. Eur Urol Oncol. 2025. PMID: 40675873. doi:10.1016/j.euo.2025.04.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。